Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer

STATUS

Recruiting
participants needed

146
sponsor

Chinese University of Hong Kong

Send

Updated on 19 February 2024

See if I qualify

cancer

adenocarcinoma

androgens

prostatectomy

enzalutamide

antiandrogen therapy

adenocarcinoma of prostate

androgen suppression

apalutamide

recurrent prostate cancer

prostate cancer

androgen deprivation

Summary

This is a prospective, open-label, randomized, controlled, cross-over trial assessing patient preference for apalutamide versus enzalutamide in 146 male patients with recurrent or metastatic hormone-sensitive prostate cancer. The primary objective is to investigate whether there is any difference in patient preference between apalutamide and enzalutamide in patients with recurrent or metastatic hormone-sensitive prostate cancer.

Description

This is a prospective, open-label, randomized, controlled, cross-over trial assessing patient preference for apalutamide versus enzalutamide in 146 male patients with recurrent or metastatic hormone-sensitive prostate cancer The primary outcome is patient preference, which serves as an indicator covering different aspects of treatment-related effects, and this would be most important in a patient's perspective. The quality of life, psychological and cognitive changes following apalutamide and enzalutamide in a comprehensive manner will be investigated.

Patient will receive two 12-weeks treatment periods with a 5-week wash-out period between the treatment periods. Patients will receive Apalutamide and Enzulutamide sequentially. Patient, physician and caregiver preferences will be assessed at the end of the second treatment period. Other secondary outcomes on health-related quality of life measures, psychological assessment scores and cognitive assessment scores shall be assessed before and the end of first treatment and second treatment period.

Details

Condition	Malignant neoplasm of prostate, Prostatic disorder
Age	18years - 100years
Treatment	Apalutamide, Enzalutamide
Clinical Study Identifier	NCT04409288
Sponsor	Chinese University of Hong Kong
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	b'18 years old or above with informed consent'
	b'Histological diagnosis of adenocarcinoma of the prostate without neuroendocrine'
	b'differentiation, signet cell, or small cell features'
	b'Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2'
	b'Androgen deprivation therapy started at least 28 days prior to randomization'
	b'Patients should be having one of the following diseases and treatment conditions:'
	b'Recurrent prostate cancer following radical prostatectomy or radiotherapy, which'
	b'do not fall into high-risk or high-volume categories'
	b'Metastatic hormone-sensitive prostate cancer, which do not fall into high-risk or'
	b'high-volume categories'
Exclusion Criteria
	b'Patients with high-volume metastatic hormone-sensitive prostate cancer, defined by the'
	b'presence of visceral metastases or four or more bone lesions with at least one beyond'
	b'the vertebral bodies and pelvis'
	b'Patients with high-risk metastatic hormone-sensitive prostate cancer, defined by'
	b'having at least two of the three following factors - a Gleason score above 7, having'
	b'at least 3 bone metastasis or presence of measurable visceral metastasis'
	b'Presence of brain metastasis'
	b'Use of bisphosphonate or denosumab within 28 days prior to randomization'
	b'Use of older anti-androgens, including flutamide and bicalutamide, for flare'
	b'protection, within 28 days prior to randomization'
	b'Prior use of chemotherapy, immunotherapy, radiopharmaceutical agents, CYP17 inhibitors'
	b'(e.g. abiraterone acetate), enzalutamide or apalutamide for the treatment of prostate'
	b'cancer or prior participation in a clinical trial of an investigational agent that'
	b'inhibits the androgen receptor or androgen synthesis'
	b'History of seizure or any condition that may predispose to seizure (e.g., neurological'
	b'disorder, prior cortical stroke or significant brain trauma)'
	b'Use of an investigational agent within 4 weeks of randomization'
	b'Hypersensitivity reaction to the active pharmaceutical ingredient'
	b'Clinically significant cardiovascular disease including the following:'
	b'Myocardial infarction within 6 months before screening;'
	b'Uncontrolled angina within 3 months before screening;'
	b'Congestive heart failure New York Heart Association class 3 or 4, or a history of'
	b'congestive heart failure New York Heart Association class 3 or 4, unless a'
	b'creening echocardiogram or multigated acquisition scan performed within 3 months'
	b'before randomization demonstrates a left ventricular ejection fraction \\u2265 50%;'
	b'History of clinically significant ventricular arrhythmias (e.g. sustained'
	b'ventricular tachycardia, ventricular fibrillation, torsades de pointes);'
	b'History of Mobitz II second-degree or third-degree heart block without a'
	b'permanent pacemaker in place;'
	b'Hypotension as indicated by systolic blood pressure < 86 millimeters of mercury'
	b'(mm Hg) at screening;'
	b'Bradycardia as indicated by a heart rate of < 45 beats per minute on the'
	b'creening electrocardiogram and on physical examination;'
	b'Uncontrolled hypertension as indicated by systolic blood pressure > 170 mm Hg or'
	b'diastolic blood pressure > 105 mm Hg at screening'
	b'Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer'
	b'disease within 3 months before randomization)'
	b'Major surgery within 28 days of randomization'
	b'Any concurrent disease, infection, or comorbid condition that interferes with the'
	b'ability of the patient to participate in the trial, which places the patient at undue'
	b'risk, or complicates the interpretation of data, in the opinion of the investigator'

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

adenocarcinoma of prostate

androgen suppression

apalutamide

recurrent prostate cancer

prostate cancer

androgen deprivation

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer